title: Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.
authors.affiliation: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Ikeda
authors.affiliation: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Shimizu
authors.affiliation: Department of Biostatistics, Kyoto University School of Public Health, Kyoto, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.affiliation: Department of Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Morimoto
authors.affiliation: Department of Gastroenterology, National Center for Global Health and Medicine Center Hospital, Tokyo, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Kojima
authors.affiliation: Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Inaba
authors.affiliation: Department of Hepatology, Osaka City University Hospital, Osaka, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Hagihara
authors.affiliation: Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Kudo
authors.affiliation: Department of Hepatobiliary and Pancreatic Surgery, Osaka National Hospital, Osaka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Nakamori
authors.affiliation: Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.affiliation: Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Sugimoto
authors.affiliation: Department of Gastroenterology, Saiseikai Utsunomiya Hospital, Tochigi, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Tahara
authors.affiliation: Department of Gastroenterology, Sapporo Kosei General Hospital, Sapporo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Ohmura
authors.affiliation: Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Yasui
authors.affiliation: Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sato
authors.affiliation: Clinical Research Center, Shikoku Cancer Center, Matsuyama, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Ishii
authors.affiliation: Department of Medical Oncology, Kyorin University, Tokyo, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Furuse
authors.affiliation: Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Okusaka
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols; D006528:Carcinoma, Hepatocellular; D002945:Cisplatin; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D000077157:Sorafenib
chemical_list: D010671:Phenylurea Compounds; D009536:Niacinamide; D000077157:Sorafenib; D002945:Cisplatin